All the news Showing 10 of 676 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Tailoring hepatitis C treatment duration to viral load responses could cut costs Keith Alcorn / 31 March 2016 Hepatitis C viral load testing during treatment can be used to predict which patients have been cured after a shorter course of treatment, potentially cutting the cost of treatment by up to ... Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4 Liz Highleyman / 02 March 2016 Sofosbuvir plus the investigational HCV NS5A inhibitor ravidasvir, with or without ribavirin, cured 95 to 100% of people with hepatitis C virus (HCV) genotype 4, the most common type in Egypt, ... AbbVie receives CHMP positive opinion for VIEKIRAX® + EXVIERA® without ribavirin for the treatment of HCV in GT1b patients with compensated cirrhosis in Europe AbbVie press release / 02 March 2016 Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low Liz Highleyman / 26 February 2016 An interferon- and ribavirin-free regimen of sofosbuvir/ledipasvir (Harvoni) taken for just 6 weeks was enough to cure hepatitis C in HIV-positive people with recent hepatitis C virus (HCV) infection if their HCV viral ... Sofosbuvir plus ribavirin shows suboptimal efficacy for acute hepatitis C Liz Highleyman / 25 February 2016 A combination of sofosbuvir (Sovaldi) and ribavirin cured more than 90% of hepatitis C in people living with HIV and acute hepatitis C virus (HCV) infection in a small study, but a similar ... RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up Regulus Therapeutics press release / 17 February 2016 Australia: Treatment Has Changed campaign Hepatitis New South Wales / 17 February 2016 U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease Gilead press release / 17 February 2016 MiR-122 inhibitor RG-101 suppresses hepatitis C virus with a single dose Liz Highleyman / 15 February 2016 A single injection of RG-101, an experimental drug that targets the micro-RNA miR-122 in liver cells, reduced hepatitis C virus (HCV) levels by more than 4 log10 in people with HCV genotypes 1, ... U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Bristol-Myers Squibb press release / 08 February 2016 ← Prev1...89101112...68Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds